Mochida Pharmaceutical (TSE:4534) reported a net profit margin of 5.7%, up from 4.3% a year earlier, with earnings surging 36.5% over the past year. Despite this progress, shares currently trade at ¥3 ...

BLAINVILLE, QC, Dec. 15, 2025 /CNW/ - Mochida Pharmaceutical Co., Ltd. (Head Office: Shinjuku-ku, Tokyo, Japan; President: Naoyuki Mochida; hereinafter "Mochida") and ...

Mochida Pharmaceutical Co., Ltd. (JP:4534) has released an update. Mochida Pharmaceutical Co., Ltd. reported a 3.3% increase in net sales for the six months ending September 30, 2024, compared to the ...

Visit a quote page and your recently viewed tickers will be displayed here.

Aaaaaaaa Aa Aa 1,062.0 +23.88% 1,315.6 ...

TOKYO, Jan 9 (Reuters) - U.S. pharmaceutical firm Wyeth has bought the global rights to develop and market an experimental pain medication from Mochida Pharmaceutical Co Ltd <4534.T>, the Japanese ...

Review quarterly and annual revenue, net income, and cash flow for Mochida Pharmaceutical Co Ltd (4534:XTKS) stock through the last fiscal year.

Determining whether Mochida Pharmaceutical—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current ...

Mochida Pharmaceutical Co. Ltd. engages in the research, development, manufacturing and sale of pharmaceuticals, healthcare products, and medical equipment. It operates through following business ...

Review the current valuation for Mochida Pharmaceutical Co Ltd (4534:XTKS) stock based on a yearly calendar providing PE ratios, cash flow, EBITDA and other company valuation information.